Clinical Research Papers:
Percutaneous computed tomography-guided cryoablation for recurrent retroperitoneal soft tissue sarcoma: a study of safety and efficacy
Metrics: PDF 704 views | HTML 1288 views | ?
Wenzhe Fan1, Lizhi Niu2,3, Yu Wang1, Yingqiang Zhang1, Xuehua Yao1, Guosheng Tan4, Jianyong Yang4,5, Jiaping Li1
1Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
2Fuda Cancer Hospital, Guangzhou, China
3Fuda Institute of Cryosurgery for Cancer, Guangzhou, China
4Department of Interventional Radiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
5Department of Medical Imaging, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
Jia-Ping Li, email: email@example.com
Keywords: computer tomography, cryoablation, retroperitoneal sarcoma, survival, response rate
Received: October 10, 2015 Accepted: April 16, 2016 Published: May 19, 2016
Aims: To evaluate the use of computed tomography image-guided percutaneous cryoablation for recurrent retroperitoneal soft tissue sarcomas (RPSs).
Results: Adverse events were limited to grades 1 and 2, included fever (n = 19), local pain (n = 11), emesis (n = 10), frostbite (n = 6), and nerve injury (n = 1). Fever was more frequent in the large tumor group (15.8%) than in small tumor group (1.9%) (P = 0.008). Median PFS and OS were 37.0 ± 7.7 months (range, 4–39 months) and 43.0 ± 5.9 months (range, 6–54 months), respectively. PFS and OS were significantly longer in the small tumor group than in the large tumor group (P = 0.011 and P = 0.015, respectively), but the response rate (82.7% vs. 72.8%, P = 0.240) did not differ significantly. On univariate analysis, tumor size, tumor invasion grade, and distant metastasis were significant prognostic factors for PFS and OS. On multivariate analysis, a tumor size ≥10 cm was an independent negative prognostic factor for PFS and OS after cryoablation (HR: 3.98, 95% CI: 1.27–12.50, P = 0.018 and HR: 4.33, 95% CI: 1.41–13.26, P = 0.010, respectively).
Materials and Methods: Data from 72 patients with recurrent RPSs who underwent percutaneous cryoablation were reviewed retrospectively. The prognostic factors for progression-free survival (PFS), overall survival (OS), and efficacy based on mRECIST criteria were analysis. Adverse events were compared according to tumor size (<10 and ≥10 cm).
Conclusion: Minimally invasive percutaneous cryoablation was safe and efficacious for recurrent RPSs.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.